Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naptumomab Estafenatox + Docetaxel in Pretreated Advanced NSCLC
NCT04880863Phase 2Completed
- Sponsor
- NeoTX Therapeutics
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of naptumomab estafenatox in non-small cell lung cancer (NSCLC), sponsored by NeoTX Therapeutics. Started Oct 2021; status: completed.
02
Drugs
naptumomab estafenatox
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04880863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880863.